STAT+: The U.S. government doesn’t have patent rights to Gilead’s remdesivir, despite investing millions in research
American taxpayers may have provided $162 million toward researching the drug remdesivir, but the federal government does not have patent rights to the treatment because the work contributed by U.S. scientists did not generate any new uses, according to a government report.
Moreover, Gilead Sciences, which discovered remdesivir, had already reached collaborative research deals with various federal agencies and universities to work on a portfolio of existing patents and patent applications, including for the remdesivir compound. And this “would have left little room for the agencies to generate their own patents, the Government Accountability Office found.
Continue to STAT+ to read the full story…
